635 related articles for article (PubMed ID: 15866704)
21. [Immunomodulatory effects of intravenous immunoglobulins].
Kazatchkine M; Mouthon L; Kaveri SV
Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S13-8. PubMed ID: 10896983
[TBL] [Abstract][Full Text] [Related]
22. Idiopathic thrombocytopenic purpura (ITP): immunomodulation by intravenous immunoglobulin (IVIg).
Imbach P; Morell A
Int Rev Immunol; 1989; 5(2):181-8. PubMed ID: 8691051
[TBL] [Abstract][Full Text] [Related]
23. Acute renal failure after high-dose intravenous immune globulin in a patient with idiopathic thrombocytopenic purpura.
Ruggeri M; Castaman G; De Nardi G; Rodeghiero F
Haematologica; 1993; 78(5):338-9. PubMed ID: 8314166
[TBL] [Abstract][Full Text] [Related]
24. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin.
Rütter A; Luger TA
J Am Acad Dermatol; 2001 Jun; 44(6):1010-24. PubMed ID: 11369915
[TBL] [Abstract][Full Text] [Related]
25. Possible lower rate of chronic ITP after IVIG for acute childhood ITP an analysis from registry I of the Intercontinental Cooperative ITP Study Group (ICIS).
Tamminga R; Berchtold W; Bruin M; Buchanan GR; Kühne T
Br J Haematol; 2009 Jul; 146(2):180-4. PubMed ID: 19466971
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin.
Ephrem A; Misra N; Hassan G; Dasgupta S; Delignat S; Duong Van Huyen JP; Chamat S; Prost F; Lacroix-Desmazes S; Kavery SV; Kazatchkine MD
Clin Exp Med; 2005 Dec; 5(4):135-40. PubMed ID: 16362793
[TBL] [Abstract][Full Text] [Related]
27. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor.
Hansen RJ; Balthasar JP
Thromb Haemost; 2002 Dec; 88(6):898-9. PubMed ID: 12529736
[TBL] [Abstract][Full Text] [Related]
28. Clinical course of children with immune thrombocytopenic purpura treated with intravenous immunoglobulin G or megadose methylprednisolone or observed without therapy.
Duru F; Fisgin T; Yarali N; Kara A
Pediatr Hematol Oncol; 2002 Jun; 19(4):219-25. PubMed ID: 12051587
[TBL] [Abstract][Full Text] [Related]
29. Autoantibody level modification in adult patients with idiopathic thrombocytopenic purpura following intravenous immunoglobulin treatment.
Levy Y; Sherer Y; Ahmed A; Fabbrizzi F; Terryberry J; Shen GQ; Peter JB; Shoenfeld Y
Nat Immun; 1998; 16(5-6):207-14. PubMed ID: 11061589
[TBL] [Abstract][Full Text] [Related]
30. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat.
Rodeghiero F
Eur J Haematol Suppl; 2008 Feb; (69):19-26. PubMed ID: 18211569
[TBL] [Abstract][Full Text] [Related]
31. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin.
Leontyev D; Katsman Y; Ma XZ; Miescher S; Käsermann F; Branch DR
Transfusion; 2012 Aug; 52(8):1799-805. PubMed ID: 22257295
[TBL] [Abstract][Full Text] [Related]
32. [Mechanism of action of immunoglobulin applied intravenously].
Kasztalska K; Ciebiada M; Górski P
Pol Merkur Lekarski; 2010 Oct; 29(172):263-8. PubMed ID: 21207645
[TBL] [Abstract][Full Text] [Related]
33. Idiopathic thrombocytopenia purpura: Treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy.
Simpson KN; Coughlin CM; Eron J; Bussel JB
Semin Hematol; 1998 Jan; 35(1 Suppl 1):58-64. PubMed ID: 9523750
[TBL] [Abstract][Full Text] [Related]
34. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1.
Schwab I; Biburger M; Krönke G; Schett G; Nimmerjahn F
Eur J Immunol; 2012 Apr; 42(4):826-30. PubMed ID: 22278120
[TBL] [Abstract][Full Text] [Related]
35. A comparative study of initial use of intravenous immunoglobulin and prednisolone treatments in childhood idiopathic thrombocytopenic purpur.
Ou CY; Hsieh KS; Chiou YH; Chang YH; Ger LP
Acta Paediatr Taiwan; 2006; 47(5):226-31. PubMed ID: 17352309
[TBL] [Abstract][Full Text] [Related]
36. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss.
Sapir T; Blank M; Shoenfeld Y
Ann N Y Acad Sci; 2005 Jun; 1051():743-78. PubMed ID: 16127014
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of platelet recovery in ITP associated with therapy.
Pang SJ; Lazarus AH
Ann Hematol; 2010 Jul; 89 Suppl 1():31-5. PubMed ID: 20179926
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of action of intravenous immune globulin in immune-mediated diseases.
Mouthon L; Kaveri SV; Spalter SH; Lacroix-Desmazes S; Lefranc C; Desai R; Kazatchkine MD
Clin Exp Immunol; 1996 May; 104 Suppl 1():3-9. PubMed ID: 8625540
[TBL] [Abstract][Full Text] [Related]
39. Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies.
Sibéril S; Elluru S; Negi VS; Ephrem A; Misra N; Delignat S; Bayary J; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
Transfus Apher Sci; 2007 Aug; 37(1):103-7. PubMed ID: 17765663
[TBL] [Abstract][Full Text] [Related]
40. Modulation of the cellular immune system by intravenous immunoglobulin.
Tha-In T; Bayry J; Metselaar HJ; Kaveri SV; Kwekkeboom J
Trends Immunol; 2008 Dec; 29(12):608-15. PubMed ID: 18926775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
